Skip to content

Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects

Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06339450
Acronym
ExpoCF
Enrollment
0
Registered
2024-04-01
Start date
2025-12-01
Completion date
2027-12-01
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis, Pulmonary

Keywords

cystic fibrosis, Environmental Exposure, exhaled breath condansate, Levels of 3-Nitrotyrosin, Hexanal, Neutrophil Elastase, level of hexanal, level of Neutrophil Elastase

Brief summary

Cystic fibrosis (CF) is the most common autosomal recessive disease that leads to early mortality in Caucasians and affects around 7500 patients in France. Progression of the disease depends on pulmonary exacerbations defined as acute deterioration of respiratory symptoms which ultimately impair lung function and quality of life. Most frequently caused by lung bacterial infections, exacerbations' effects include increased cough, increased sputum production, increased use of antibiotics, dyspnea and decreased lung function. The phenotypic variability of CF suggests the implication of other contributors especially to the CF airway disease. Beside genetic and epigenetic alterations, environmental factors - e.g tobacco smoke, air pollution, temperature changes, food intake - appear as relevant candidates. A previous review has discussed current knowledge on the effects of air pollution on the course of CF disease. Although scarce, the existing epidemiological andexperimental literature suggests a link between exposure to air pollutants and adverse health effects.Although scarce, the existing epidemiological and experimental literature suggests a link between exposure to air pollutants and adverse health effects. The EU sponsored REMEDIA project (Impact of exposome on the course of lung diseases, Grant agreement ID 874753) contributes to the understanding of the influence of the exposome on chronic obstructive pulmonary disease (COPD) and CF. Objective of work package 3 within the REMEDIA project is the development of a mobile environmental sensor toolbox that is capable to assess the external exposome. The biomarkertoolbox was developed and tested in a proof-of-concept study carried out in healthy volunteers. The next step is to validate the collectionof exhaled breath condensate (EBC) in a real-life study. In this aim, the objective of the present study will be to assess the feasibility of EBC collection in CF patients and healthy individuals

Interventions

OTHERwalk tours

* During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other "green spaces", including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space. * During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break.

Sponsors

Centre Hospitalier Intercommunal Creteil
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Normal blood test * Negative Cotinine test * Protocole (RiPH2) * Normal ECG * Normal alcohol test * Lung function with FEV1 predicted ≥ 40% at spirometry.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Collection of exhaled breath condensate (EBC) for biomarker analysisday 1Levels of 3-Nitrotyrosin, Hexanal, Neutrophil Elastase in EBC

Secondary

MeasureTime frameDescription
Dysfunction or misused, failure, of EBC and sensor devicedays 10rate of Dysfunction or misused, failure, of EBC and sensor device
Show correlation of biomarker signal with environmental sensor system in a clinical challenge setting in healthy and CF patients.days 5Correlation of environmental exposome signal biomark
Describe differences in CF subjects vs. healthy controlsdays 5Comparison of environmental exposome signal biomarker and environmental sensor measures in healthy individuals and CF patients
Impact of environment exposome on health status and lung functiondays 5Lung function testing and health questionnaire score before and after working trial in urban and green zone

Contacts

PRINCIPAL_INVESTIGATORralph Epaud

CHI CRETEIL

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026